nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyclophosphamide—CYP3A7—Sorafenib—thyroid cancer	0.0727	0.116	CbGbCtD
Cyclophosphamide—CYP3A7-CYP3A51P—Sorafenib—thyroid cancer	0.0727	0.116	CbGbCtD
Cyclophosphamide—CYP2B6—Sorafenib—thyroid cancer	0.0692	0.111	CbGbCtD
Cyclophosphamide—CYP3A5—Sorafenib—thyroid cancer	0.0545	0.0873	CbGbCtD
Cyclophosphamide—CYP2C8—Sorafenib—thyroid cancer	0.0524	0.084	CbGbCtD
Cyclophosphamide—CYP2C19—Sorafenib—thyroid cancer	0.044	0.0705	CbGbCtD
Cyclophosphamide—CYP2B6—Doxorubicin—thyroid cancer	0.042	0.0673	CbGbCtD
Cyclophosphamide—CYP2C9—Sorafenib—thyroid cancer	0.0365	0.0586	CbGbCtD
Cyclophosphamide—ABCB1—Sorafenib—thyroid cancer	0.0355	0.0568	CbGbCtD
Cyclophosphamide—CYP3A4—Vandetanib—thyroid cancer	0.0353	0.0565	CbGbCtD
Cyclophosphamide—CYP2D6—Sorafenib—thyroid cancer	0.0334	0.0536	CbGbCtD
Cyclophosphamide—ABCB1—Doxorubicin—thyroid cancer	0.0215	0.0345	CbGbCtD
Cyclophosphamide—CYP3A4—Sorafenib—thyroid cancer	0.0213	0.0341	CbGbCtD
Cyclophosphamide—CYP2D6—Doxorubicin—thyroid cancer	0.0203	0.0325	CbGbCtD
Cyclophosphamide—CYP3A4—Doxorubicin—thyroid cancer	0.0129	0.0207	CbGbCtD
Cyclophosphamide—Cough—Sorafenib—thyroid cancer	0.000413	0.0011	CcSEcCtD
Cyclophosphamide—Inflammation—Epirubicin—thyroid cancer	0.000413	0.0011	CcSEcCtD
Cyclophosphamide—Asthenia—Vandetanib—thyroid cancer	0.000411	0.00109	CcSEcCtD
Cyclophosphamide—Viral infection—Doxorubicin—thyroid cancer	0.00041	0.00109	CcSEcCtD
Cyclophosphamide—Hypertension—Sorafenib—thyroid cancer	0.000409	0.00109	CcSEcCtD
Cyclophosphamide—Blood uric acid increased—Epirubicin—thyroid cancer	0.000408	0.00108	CcSEcCtD
Cyclophosphamide—Hyperbilirubinaemia—Doxorubicin—thyroid cancer	0.000407	0.00108	CcSEcCtD
Cyclophosphamide—Pruritus—Vandetanib—thyroid cancer	0.000405	0.00108	CcSEcCtD
Cyclophosphamide—Myalgia—Sorafenib—thyroid cancer	0.000403	0.00107	CcSEcCtD
Cyclophosphamide—Arthralgia—Sorafenib—thyroid cancer	0.000403	0.00107	CcSEcCtD
Cyclophosphamide—Lacrimation increased—Doxorubicin—thyroid cancer	0.000402	0.00107	CcSEcCtD
Cyclophosphamide—Ventricular tachycardia—Epirubicin—thyroid cancer	0.0004	0.00106	CcSEcCtD
Cyclophosphamide—Pulmonary embolism—Epirubicin—thyroid cancer	0.0004	0.00106	CcSEcCtD
Cyclophosphamide—Hyperuricaemia—Doxorubicin—thyroid cancer	0.000399	0.00106	CcSEcCtD
Cyclophosphamide—Hyperkalaemia—Epirubicin—thyroid cancer	0.000393	0.00105	CcSEcCtD
Cyclophosphamide—Diarrhoea—Vandetanib—thyroid cancer	0.000392	0.00104	CcSEcCtD
Cyclophosphamide—Ulcer—Doxorubicin—thyroid cancer	0.000392	0.00104	CcSEcCtD
Cyclophosphamide—Blood bilirubin increased—Doxorubicin—thyroid cancer	0.000392	0.00104	CcSEcCtD
Cyclophosphamide—Cystitis noninfective—Epirubicin—thyroid cancer	0.000391	0.00104	CcSEcCtD
Cyclophosphamide—Influenza like illness—Epirubicin—thyroid cancer	0.000389	0.00103	CcSEcCtD
Cyclophosphamide—Cystitis—Epirubicin—thyroid cancer	0.000387	0.00103	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Sorafenib—thyroid cancer	0.000387	0.00103	CcSEcCtD
Cyclophosphamide—Colitis—Epirubicin—thyroid cancer	0.000384	0.00102	CcSEcCtD
Cyclophosphamide—Infection—Sorafenib—thyroid cancer	0.000384	0.00102	CcSEcCtD
Cyclophosphamide—Inflammation—Doxorubicin—thyroid cancer	0.000382	0.00102	CcSEcCtD
Cyclophosphamide—Shock—Sorafenib—thyroid cancer	0.00038	0.00101	CcSEcCtD
Cyclophosphamide—Fluid retention—Epirubicin—thyroid cancer	0.00038	0.00101	CcSEcCtD
Cyclophosphamide—Dizziness—Vandetanib—thyroid cancer	0.000379	0.00101	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Sorafenib—thyroid cancer	0.000378	0.00101	CcSEcCtD
Cyclophosphamide—Blood uric acid increased—Doxorubicin—thyroid cancer	0.000377	0.001	CcSEcCtD
Cyclophosphamide—Pulmonary embolism—Doxorubicin—thyroid cancer	0.000371	0.000985	CcSEcCtD
Cyclophosphamide—Ventricular tachycardia—Doxorubicin—thyroid cancer	0.000371	0.000985	CcSEcCtD
Cyclophosphamide—Anorexia—Sorafenib—thyroid cancer	0.000368	0.00098	CcSEcCtD
Cyclophosphamide—Vomiting—Vandetanib—thyroid cancer	0.000364	0.000969	CcSEcCtD
Cyclophosphamide—Hyperkalaemia—Doxorubicin—thyroid cancer	0.000364	0.000968	CcSEcCtD
Cyclophosphamide—Neoplasm—Epirubicin—thyroid cancer	0.000362	0.000963	CcSEcCtD
Cyclophosphamide—Mouth ulceration—Epirubicin—thyroid cancer	0.000362	0.000963	CcSEcCtD
Cyclophosphamide—Bladder pain—Epirubicin—thyroid cancer	0.000362	0.000963	CcSEcCtD
Cyclophosphamide—Cystitis noninfective—Doxorubicin—thyroid cancer	0.000362	0.000962	CcSEcCtD
Cyclophosphamide—Rash—Vandetanib—thyroid cancer	0.000361	0.000961	CcSEcCtD
Cyclophosphamide—Dermatitis—Vandetanib—thyroid cancer	0.000361	0.00096	CcSEcCtD
Cyclophosphamide—Influenza like illness—Doxorubicin—thyroid cancer	0.00036	0.000957	CcSEcCtD
Cyclophosphamide—Headache—Vandetanib—thyroid cancer	0.000359	0.000955	CcSEcCtD
Cyclophosphamide—Cystitis—Doxorubicin—thyroid cancer	0.000358	0.000951	CcSEcCtD
Cyclophosphamide—Pulmonary oedema—Epirubicin—thyroid cancer	0.000356	0.000948	CcSEcCtD
Cyclophosphamide—Colitis—Doxorubicin—thyroid cancer	0.000356	0.000946	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.000352	0.000936	CcSEcCtD
Cyclophosphamide—Fluid retention—Doxorubicin—thyroid cancer	0.000352	0.000935	CcSEcCtD
Cyclophosphamide—Sepsis—Epirubicin—thyroid cancer	0.000347	0.000924	CcSEcCtD
Cyclophosphamide—Dyspnoea—Sorafenib—thyroid cancer	0.000345	0.000916	CcSEcCtD
Cyclophosphamide—Nausea—Vandetanib—thyroid cancer	0.00034	0.000905	CcSEcCtD
Cyclophosphamide—Phlebitis—Epirubicin—thyroid cancer	0.000337	0.000897	CcSEcCtD
Cyclophosphamide—Decreased appetite—Sorafenib—thyroid cancer	0.000336	0.000893	CcSEcCtD
Cyclophosphamide—Bladder pain—Doxorubicin—thyroid cancer	0.000335	0.000891	CcSEcCtD
Cyclophosphamide—Mouth ulceration—Doxorubicin—thyroid cancer	0.000335	0.000891	CcSEcCtD
Cyclophosphamide—Neoplasm—Doxorubicin—thyroid cancer	0.000335	0.000891	CcSEcCtD
Cyclophosphamide—Diabetes mellitus—Epirubicin—thyroid cancer	0.000334	0.000889	CcSEcCtD
Cyclophosphamide—Fatigue—Sorafenib—thyroid cancer	0.000333	0.000886	CcSEcCtD
Cyclophosphamide—Hepatic function abnormal—Epirubicin—thyroid cancer	0.000333	0.000884	CcSEcCtD
Cyclophosphamide—Pain—Sorafenib—thyroid cancer	0.000331	0.000879	CcSEcCtD
Cyclophosphamide—Constipation—Sorafenib—thyroid cancer	0.000331	0.000879	CcSEcCtD
Cyclophosphamide—Pulmonary oedema—Doxorubicin—thyroid cancer	0.00033	0.000877	CcSEcCtD
Cyclophosphamide—Hepatic failure—Epirubicin—thyroid cancer	0.000323	0.00086	CcSEcCtD
Cyclophosphamide—Sepsis—Doxorubicin—thyroid cancer	0.000322	0.000855	CcSEcCtD
Cyclophosphamide—Cardiac failure congestive—Epirubicin—thyroid cancer	0.000321	0.000852	CcSEcCtD
Cyclophosphamide—Renal failure acute—Epirubicin—thyroid cancer	0.000315	0.000837	CcSEcCtD
Cyclophosphamide—Phlebitis—Doxorubicin—thyroid cancer	0.000312	0.00083	CcSEcCtD
Cyclophosphamide—Hot flush—Epirubicin—thyroid cancer	0.000311	0.000826	CcSEcCtD
Cyclophosphamide—Diabetes mellitus—Doxorubicin—thyroid cancer	0.000309	0.000822	CcSEcCtD
Cyclophosphamide—Menopausal symptoms—Epirubicin—thyroid cancer	0.000308	0.000819	CcSEcCtD
Cyclophosphamide—Hepatic function abnormal—Doxorubicin—thyroid cancer	0.000308	0.000818	CcSEcCtD
Cyclophosphamide—Urticaria—Sorafenib—thyroid cancer	0.000307	0.000817	CcSEcCtD
Cyclophosphamide—Body temperature increased—Sorafenib—thyroid cancer	0.000306	0.000813	CcSEcCtD
Cyclophosphamide—Renal impairment—Epirubicin—thyroid cancer	0.000305	0.000812	CcSEcCtD
Cyclophosphamide—Dermatitis bullous—Epirubicin—thyroid cancer	0.000304	0.000809	CcSEcCtD
Cyclophosphamide—Hepatic failure—Doxorubicin—thyroid cancer	0.000299	0.000796	CcSEcCtD
Cyclophosphamide—Cardiac failure—Epirubicin—thyroid cancer	0.000298	0.000792	CcSEcCtD
Cyclophosphamide—Cardiac failure congestive—Doxorubicin—thyroid cancer	0.000297	0.000789	CcSEcCtD
Cyclophosphamide—Hyponatraemia—Epirubicin—thyroid cancer	0.000292	0.000776	CcSEcCtD
Cyclophosphamide—Renal failure acute—Doxorubicin—thyroid cancer	0.000291	0.000775	CcSEcCtD
Cyclophosphamide—Gastrointestinal haemorrhage—Epirubicin—thyroid cancer	0.000291	0.000773	CcSEcCtD
Cyclophosphamide—Hot flush—Doxorubicin—thyroid cancer	0.000288	0.000764	CcSEcCtD
Cyclophosphamide—Menopausal symptoms—Doxorubicin—thyroid cancer	0.000285	0.000758	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Sorafenib—thyroid cancer	0.000285	0.000757	CcSEcCtD
Cyclophosphamide—Renal impairment—Doxorubicin—thyroid cancer	0.000283	0.000751	CcSEcCtD
Cyclophosphamide—Dermatitis bullous—Doxorubicin—thyroid cancer	0.000281	0.000748	CcSEcCtD
Cyclophosphamide—Asthenia—Sorafenib—thyroid cancer	0.000277	0.000737	CcSEcCtD
Cyclophosphamide—Cardiac arrest—Epirubicin—thyroid cancer	0.000276	0.000735	CcSEcCtD
Cyclophosphamide—Cardiac failure—Doxorubicin—thyroid cancer	0.000276	0.000733	CcSEcCtD
Cyclophosphamide—Pruritus—Sorafenib—thyroid cancer	0.000273	0.000727	CcSEcCtD
Cyclophosphamide—Hyponatraemia—Doxorubicin—thyroid cancer	0.00027	0.000718	CcSEcCtD
Cyclophosphamide—Gastrointestinal haemorrhage—Doxorubicin—thyroid cancer	0.000269	0.000715	CcSEcCtD
Cyclophosphamide—Diarrhoea—Sorafenib—thyroid cancer	0.000264	0.000703	CcSEcCtD
Cyclophosphamide—Toxic epidermal necrolysis—Epirubicin—thyroid cancer	0.000262	0.000696	CcSEcCtD
Cyclophosphamide—Nasopharyngitis—Epirubicin—thyroid cancer	0.00026	0.000691	CcSEcCtD
Cyclophosphamide—Cardiac arrest—Doxorubicin—thyroid cancer	0.000256	0.00068	CcSEcCtD
Cyclophosphamide—Dizziness—Sorafenib—thyroid cancer	0.000256	0.00068	CcSEcCtD
Cyclophosphamide—Vomiting—Sorafenib—thyroid cancer	0.000246	0.000654	CcSEcCtD
Cyclophosphamide—Rash—Sorafenib—thyroid cancer	0.000244	0.000648	CcSEcCtD
Cyclophosphamide—Dermatitis—Sorafenib—thyroid cancer	0.000244	0.000647	CcSEcCtD
Cyclophosphamide—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	0.000242	0.000644	CcSEcCtD
Cyclophosphamide—Headache—Sorafenib—thyroid cancer	0.000242	0.000644	CcSEcCtD
Cyclophosphamide—Nasopharyngitis—Doxorubicin—thyroid cancer	0.000241	0.000639	CcSEcCtD
Cyclophosphamide—Pancytopenia—Epirubicin—thyroid cancer	0.000239	0.000634	CcSEcCtD
Cyclophosphamide—Nausea—Sorafenib—thyroid cancer	0.00023	0.000611	CcSEcCtD
Cyclophosphamide—Weight increased—Epirubicin—thyroid cancer	0.000229	0.000608	CcSEcCtD
Cyclophosphamide—Hyperglycaemia—Epirubicin—thyroid cancer	0.000227	0.000603	CcSEcCtD
Cyclophosphamide—Pneumonia—Epirubicin—thyroid cancer	0.000225	0.000599	CcSEcCtD
Cyclophosphamide—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.000222	0.00059	CcSEcCtD
Cyclophosphamide—Pancytopenia—Doxorubicin—thyroid cancer	0.000221	0.000587	CcSEcCtD
Cyclophosphamide—Renal failure—Epirubicin—thyroid cancer	0.00022	0.000585	CcSEcCtD
Cyclophosphamide—Neuropathy peripheral—Epirubicin—thyroid cancer	0.00022	0.000584	CcSEcCtD
Cyclophosphamide—Jaundice—Epirubicin—thyroid cancer	0.000218	0.000581	CcSEcCtD
Cyclophosphamide—Stomatitis—Epirubicin—thyroid cancer	0.000218	0.000581	CcSEcCtD
Cyclophosphamide—Conjunctivitis—Epirubicin—thyroid cancer	0.000218	0.000579	CcSEcCtD
Cyclophosphamide—Sweating—Epirubicin—thyroid cancer	0.000215	0.000571	CcSEcCtD
Cyclophosphamide—Haematuria—Epirubicin—thyroid cancer	0.000214	0.000568	CcSEcCtD
Cyclophosphamide—Weight increased—Doxorubicin—thyroid cancer	0.000212	0.000562	CcSEcCtD
Cyclophosphamide—Hyperglycaemia—Doxorubicin—thyroid cancer	0.00021	0.000558	CcSEcCtD
Cyclophosphamide—Agranulocytosis—Epirubicin—thyroid cancer	0.000209	0.000556	CcSEcCtD
Cyclophosphamide—Pneumonia—Doxorubicin—thyroid cancer	0.000208	0.000554	CcSEcCtD
Cyclophosphamide—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.000205	0.000546	CcSEcCtD
Cyclophosphamide—Bradycardia—Epirubicin—thyroid cancer	0.000205	0.000544	CcSEcCtD
Cyclophosphamide—Renal failure—Doxorubicin—thyroid cancer	0.000204	0.000542	CcSEcCtD
Cyclophosphamide—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.000203	0.00054	CcSEcCtD
Cyclophosphamide—Haemoglobin—Epirubicin—thyroid cancer	0.000202	0.000537	CcSEcCtD
Cyclophosphamide—Stomatitis—Doxorubicin—thyroid cancer	0.000202	0.000537	CcSEcCtD
Cyclophosphamide—Jaundice—Doxorubicin—thyroid cancer	0.000202	0.000537	CcSEcCtD
Cyclophosphamide—Rhinitis—Epirubicin—thyroid cancer	0.000202	0.000536	CcSEcCtD
Cyclophosphamide—Conjunctivitis—Doxorubicin—thyroid cancer	0.000201	0.000536	CcSEcCtD
Cyclophosphamide—Hepatitis—Epirubicin—thyroid cancer	0.000201	0.000535	CcSEcCtD
Cyclophosphamide—Haemorrhage—Epirubicin—thyroid cancer	0.000201	0.000535	CcSEcCtD
Cyclophosphamide—Hypoaesthesia—Epirubicin—thyroid cancer	0.0002	0.000532	CcSEcCtD
Cyclophosphamide—Sweating—Doxorubicin—thyroid cancer	0.000199	0.000528	CcSEcCtD
Cyclophosphamide—Haematuria—Doxorubicin—thyroid cancer	0.000198	0.000525	CcSEcCtD
Cyclophosphamide—Visual impairment—Epirubicin—thyroid cancer	0.000194	0.000515	CcSEcCtD
Cyclophosphamide—Agranulocytosis—Doxorubicin—thyroid cancer	0.000193	0.000514	CcSEcCtD
Cyclophosphamide—Erythema multiforme—Epirubicin—thyroid cancer	0.00019	0.000506	CcSEcCtD
Cyclophosphamide—Bradycardia—Doxorubicin—thyroid cancer	0.000189	0.000504	CcSEcCtD
Cyclophosphamide—Tinnitus—Epirubicin—thyroid cancer	0.000187	0.000499	CcSEcCtD
Cyclophosphamide—Haemoglobin—Doxorubicin—thyroid cancer	0.000187	0.000497	CcSEcCtD
Cyclophosphamide—Flushing—Epirubicin—thyroid cancer	0.000187	0.000496	CcSEcCtD
Cyclophosphamide—Rhinitis—Doxorubicin—thyroid cancer	0.000187	0.000496	CcSEcCtD
Cyclophosphamide—Haemorrhage—Doxorubicin—thyroid cancer	0.000186	0.000495	CcSEcCtD
Cyclophosphamide—Hepatitis—Doxorubicin—thyroid cancer	0.000186	0.000495	CcSEcCtD
Cyclophosphamide—Hypoaesthesia—Doxorubicin—thyroid cancer	0.000185	0.000492	CcSEcCtD
Cyclophosphamide—Chills—Epirubicin—thyroid cancer	0.00018	0.00048	CcSEcCtD
Cyclophosphamide—Arrhythmia—Epirubicin—thyroid cancer	0.00018	0.000478	CcSEcCtD
Cyclophosphamide—Visual impairment—Doxorubicin—thyroid cancer	0.000179	0.000477	CcSEcCtD
Cyclophosphamide—Alopecia—Epirubicin—thyroid cancer	0.000178	0.000472	CcSEcCtD
Cyclophosphamide—Erythema multiforme—Doxorubicin—thyroid cancer	0.000176	0.000468	CcSEcCtD
Cyclophosphamide—Erythema—Epirubicin—thyroid cancer	0.000175	0.000465	CcSEcCtD
Cyclophosphamide—Tinnitus—Doxorubicin—thyroid cancer	0.000173	0.000461	CcSEcCtD
Cyclophosphamide—Flushing—Doxorubicin—thyroid cancer	0.000173	0.000459	CcSEcCtD
Cyclophosphamide—Dysgeusia—Epirubicin—thyroid cancer	0.000171	0.000456	CcSEcCtD
Cyclophosphamide—Muscle spasms—Epirubicin—thyroid cancer	0.000168	0.000447	CcSEcCtD
Cyclophosphamide—Chills—Doxorubicin—thyroid cancer	0.000167	0.000444	CcSEcCtD
Cyclophosphamide—Arrhythmia—Doxorubicin—thyroid cancer	0.000166	0.000442	CcSEcCtD
Cyclophosphamide—Vision blurred—Epirubicin—thyroid cancer	0.000165	0.000439	CcSEcCtD
Cyclophosphamide—Alopecia—Doxorubicin—thyroid cancer	0.000164	0.000437	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Epirubicin—thyroid cancer	0.000162	0.000432	CcSEcCtD
Cyclophosphamide—Erythema—Doxorubicin—thyroid cancer	0.000162	0.000431	CcSEcCtD
Cyclophosphamide—Anaemia—Epirubicin—thyroid cancer	0.000162	0.00043	CcSEcCtD
Cyclophosphamide—Agitation—Epirubicin—thyroid cancer	0.000161	0.000428	CcSEcCtD
Cyclophosphamide—Dysgeusia—Doxorubicin—thyroid cancer	0.000159	0.000422	CcSEcCtD
Cyclophosphamide—Malaise—Epirubicin—thyroid cancer	0.000158	0.00042	CcSEcCtD
Cyclophosphamide—Leukopenia—Epirubicin—thyroid cancer	0.000157	0.000417	CcSEcCtD
Cyclophosphamide—Muscle spasms—Doxorubicin—thyroid cancer	0.000156	0.000414	CcSEcCtD
Cyclophosphamide—Palpitations—Epirubicin—thyroid cancer	0.000155	0.000411	CcSEcCtD
Cyclophosphamide—Cough—Epirubicin—thyroid cancer	0.000153	0.000406	CcSEcCtD
Cyclophosphamide—Vision blurred—Doxorubicin—thyroid cancer	0.000153	0.000406	CcSEcCtD
Cyclophosphamide—Convulsion—Epirubicin—thyroid cancer	0.000152	0.000403	CcSEcCtD
Cyclophosphamide—Hypertension—Epirubicin—thyroid cancer	0.000151	0.000402	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Doxorubicin—thyroid cancer	0.00015	0.0004	CcSEcCtD
Cyclophosphamide—Anaemia—Doxorubicin—thyroid cancer	0.00015	0.000398	CcSEcCtD
Cyclophosphamide—Chest pain—Epirubicin—thyroid cancer	0.000149	0.000396	CcSEcCtD
Cyclophosphamide—Arthralgia—Epirubicin—thyroid cancer	0.000149	0.000396	CcSEcCtD
Cyclophosphamide—Myalgia—Epirubicin—thyroid cancer	0.000149	0.000396	CcSEcCtD
Cyclophosphamide—Agitation—Doxorubicin—thyroid cancer	0.000149	0.000396	CcSEcCtD
Cyclophosphamide—Discomfort—Epirubicin—thyroid cancer	0.000147	0.000392	CcSEcCtD
Cyclophosphamide—Malaise—Doxorubicin—thyroid cancer	0.000146	0.000388	CcSEcCtD
Cyclophosphamide—Leukopenia—Doxorubicin—thyroid cancer	0.000145	0.000385	CcSEcCtD
Cyclophosphamide—Confusional state—Epirubicin—thyroid cancer	0.000144	0.000383	CcSEcCtD
Cyclophosphamide—Palpitations—Doxorubicin—thyroid cancer	0.000143	0.000381	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Epirubicin—thyroid cancer	0.000143	0.00038	CcSEcCtD
Cyclophosphamide—Oedema—Epirubicin—thyroid cancer	0.000143	0.00038	CcSEcCtD
Cyclophosphamide—Infection—Epirubicin—thyroid cancer	0.000142	0.000377	CcSEcCtD
Cyclophosphamide—Cough—Doxorubicin—thyroid cancer	0.000141	0.000376	CcSEcCtD
Cyclophosphamide—Shock—Epirubicin—thyroid cancer	0.000141	0.000374	CcSEcCtD
Cyclophosphamide—Convulsion—Doxorubicin—thyroid cancer	0.00014	0.000373	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Epirubicin—thyroid cancer	0.00014	0.000372	CcSEcCtD
Cyclophosphamide—Hypertension—Doxorubicin—thyroid cancer	0.00014	0.000372	CcSEcCtD
Cyclophosphamide—Tachycardia—Epirubicin—thyroid cancer	0.000139	0.000371	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Epirubicin—thyroid cancer	0.000138	0.000367	CcSEcCtD
Cyclophosphamide—Chest pain—Doxorubicin—thyroid cancer	0.000138	0.000367	CcSEcCtD
Cyclophosphamide—Arthralgia—Doxorubicin—thyroid cancer	0.000138	0.000367	CcSEcCtD
Cyclophosphamide—Myalgia—Doxorubicin—thyroid cancer	0.000138	0.000367	CcSEcCtD
Cyclophosphamide—Discomfort—Doxorubicin—thyroid cancer	0.000136	0.000362	CcSEcCtD
Cyclophosphamide—Anorexia—Epirubicin—thyroid cancer	0.000136	0.000362	CcSEcCtD
Cyclophosphamide—Hypotension—Epirubicin—thyroid cancer	0.000133	0.000355	CcSEcCtD
Cyclophosphamide—Confusional state—Doxorubicin—thyroid cancer	0.000133	0.000354	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000132	0.000351	CcSEcCtD
Cyclophosphamide—Oedema—Doxorubicin—thyroid cancer	0.000132	0.000351	CcSEcCtD
Cyclophosphamide—Infection—Doxorubicin—thyroid cancer	0.000131	0.000349	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.00013	0.000346	CcSEcCtD
Cyclophosphamide—Shock—Doxorubicin—thyroid cancer	0.00013	0.000346	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000129	0.000344	CcSEcCtD
Cyclophosphamide—Tachycardia—Doxorubicin—thyroid cancer	0.000129	0.000343	CcSEcCtD
Cyclophosphamide—Paraesthesia—Epirubicin—thyroid cancer	0.000128	0.000341	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000128	0.00034	CcSEcCtD
Cyclophosphamide—Dyspnoea—Epirubicin—thyroid cancer	0.000127	0.000339	CcSEcCtD
Cyclophosphamide—Anorexia—Doxorubicin—thyroid cancer	0.000126	0.000335	CcSEcCtD
Cyclophosphamide—Decreased appetite—Epirubicin—thyroid cancer	0.000124	0.00033	CcSEcCtD
Cyclophosphamide—Hypotension—Doxorubicin—thyroid cancer	0.000124	0.000328	CcSEcCtD
Cyclophosphamide—Fatigue—Epirubicin—thyroid cancer	0.000123	0.000327	CcSEcCtD
Cyclophosphamide—Constipation—Epirubicin—thyroid cancer	0.000122	0.000325	CcSEcCtD
Cyclophosphamide—Pain—Epirubicin—thyroid cancer	0.000122	0.000325	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.00012	0.00032	CcSEcCtD
Cyclophosphamide—Paraesthesia—Doxorubicin—thyroid cancer	0.000119	0.000316	CcSEcCtD
Cyclophosphamide—Dyspnoea—Doxorubicin—thyroid cancer	0.000118	0.000313	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Epirubicin—thyroid cancer	0.000118	0.000313	CcSEcCtD
Cyclophosphamide—Decreased appetite—Doxorubicin—thyroid cancer	0.000115	0.000306	CcSEcCtD
Cyclophosphamide—Fatigue—Doxorubicin—thyroid cancer	0.000114	0.000303	CcSEcCtD
Cyclophosphamide—Urticaria—Epirubicin—thyroid cancer	0.000113	0.000302	CcSEcCtD
Cyclophosphamide—Pain—Doxorubicin—thyroid cancer	0.000113	0.000301	CcSEcCtD
Cyclophosphamide—Constipation—Doxorubicin—thyroid cancer	0.000113	0.000301	CcSEcCtD
Cyclophosphamide—Body temperature increased—Epirubicin—thyroid cancer	0.000113	0.0003	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Doxorubicin—thyroid cancer	0.000109	0.00029	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Epirubicin—thyroid cancer	0.000105	0.00028	CcSEcCtD
Cyclophosphamide—Urticaria—Doxorubicin—thyroid cancer	0.000105	0.000279	CcSEcCtD
Cyclophosphamide—Body temperature increased—Doxorubicin—thyroid cancer	0.000104	0.000278	CcSEcCtD
Cyclophosphamide—Asthenia—Epirubicin—thyroid cancer	0.000103	0.000273	CcSEcCtD
Cyclophosphamide—Pruritus—Epirubicin—thyroid cancer	0.000101	0.000269	CcSEcCtD
Cyclophosphamide—Diarrhoea—Epirubicin—thyroid cancer	9.77e-05	0.00026	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Doxorubicin—thyroid cancer	9.74e-05	0.000259	CcSEcCtD
Cyclophosphamide—Asthenia—Doxorubicin—thyroid cancer	9.48e-05	0.000252	CcSEcCtD
Cyclophosphamide—Dizziness—Epirubicin—thyroid cancer	9.45e-05	0.000251	CcSEcCtD
Cyclophosphamide—Pruritus—Doxorubicin—thyroid cancer	9.35e-05	0.000249	CcSEcCtD
Cyclophosphamide—Vomiting—Epirubicin—thyroid cancer	9.08e-05	0.000242	CcSEcCtD
Cyclophosphamide—Diarrhoea—Doxorubicin—thyroid cancer	9.04e-05	0.00024	CcSEcCtD
Cyclophosphamide—Rash—Epirubicin—thyroid cancer	9.01e-05	0.00024	CcSEcCtD
Cyclophosphamide—Dermatitis—Epirubicin—thyroid cancer	9e-05	0.000239	CcSEcCtD
Cyclophosphamide—Headache—Epirubicin—thyroid cancer	8.95e-05	0.000238	CcSEcCtD
Cyclophosphamide—Dizziness—Doxorubicin—thyroid cancer	8.74e-05	0.000232	CcSEcCtD
Cyclophosphamide—Nausea—Epirubicin—thyroid cancer	8.49e-05	0.000226	CcSEcCtD
Cyclophosphamide—Vomiting—Doxorubicin—thyroid cancer	8.4e-05	0.000223	CcSEcCtD
Cyclophosphamide—Rash—Doxorubicin—thyroid cancer	8.33e-05	0.000222	CcSEcCtD
Cyclophosphamide—Dermatitis—Doxorubicin—thyroid cancer	8.33e-05	0.000221	CcSEcCtD
Cyclophosphamide—Headache—Doxorubicin—thyroid cancer	8.28e-05	0.00022	CcSEcCtD
Cyclophosphamide—Nausea—Doxorubicin—thyroid cancer	7.85e-05	0.000209	CcSEcCtD
